On August 2, 2024, Vice Chancellor for the Office of Research & Creative Activities (ORCA) Roger Wakimoto announced that effective October 1, 2024 overhead rate for industry funded clinical trials will increase from 26% to 33% of total direct costs (TDC). Consistent with the rates of other UC sister campuses, the 7% increase will be used by UCLA to reinvest in infrastructure, improvements in clinical trials administration and support services. The 33% indirect rate will be applicable to new clinical trial contracts executed by the Clinical Trial Contracting & Strategic Relations (CTC-SR) unit with a UCLA IRB application creation date on or after October 1, 2024.
Please reference the table in the BruinPost for guidance and applicability of new or legacy industry clinical trial indirect rates. Questions should be sent to your assigned CTC-SR Industry Clinical Trial Contracts Officer or email: clinicaltrials@mednet.ucla.edu.
